Dennis Fournogerakis, Esin Izat and Dan Wetherill on transforming forecasting for orphan drugs

Share on facebook
Share on twitter
Share on linkedin

To successfully commercialize orphan drugs, biopharma companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities. In Pharmaceutical Executive, Dennis Fournogerakis, Esin Izat and Dan Wetherill describe how companies can start this process by transforming their forecasting efforts.